Farzana, Refath Jones, Lim S Rahman, Md Anisur Sands, Kirsty van Tonder, Andries J Portal, Edward Criollo, Jose Munoz Parkhill, Julian Guest, Martyn F Watkins, W John
...
Published in
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
10.6% patients were CRE positive. Only 27% patients were prescribed at least 1 antibiotic to which infecting pathogen was susceptible. Burn and ICU admission and antibiotics exposures facilitate CRE acquisition. Escherichia coli ST167 was the dominant CRE clone. Given the high prevalence of multidrug resistance (MDR) across South Asian (SA) hospita...
Muller, Matthew P Mishra, Sharmistha McGeer, Allison Patel, Samir Gubbay, Jonathan Hasso, Maan Chan, Adrienne K Kozak, Robert Leis, Jerome A Tan, Darrell S
...
Published in
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Person, Anna K Armstrong, Wendy S Evans, Tyler Fangman, John J W Goldstein, Robert H Haddad, Marwan Jain, Mamta K Keeshin, Susana Tookes, Hansel E Weddle, Andrea L
...
Published in
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
While we have the tools to achieve this goal, the persistent barriers to healthcare services experienced by too many individuals will need to be addressed to make significant progress and improve the health and quality of life of all people with human immunodeficiency virus (HIV). The necessary structural changes require actions by federal, state, ...
Siegrist, Emily A Sassine, Joseph
Published in
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Mpox virus is an emergent human pathogen. While it is less lethal than smallpox, it can still cause significant morbidity and mortality. In this review, we explore 3 antiviral agents with activity against mpox and other orthopoxviruses: cidofovir, brincidofovir, and tecovirimat. Cidofovir, and its prodrug brincidofovir, are inhibitors of DNA replic...
Dedrick, Rebekah M Smith, Bailey E Cristinziano, Madison Freeman, Krista G Jacobs-Sera, Deborah Belessis, Yvonne Whitney Brown, A Cohen, Keira A Davidson, Rebecca M van Duin, David
...
Published in
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Nontuberculous Mycobacterium infections, particularly Mycobacterium abscessus, are increasingly common among patients with cystic fibrosis and chronic bronchiectatic lung diseases. Treatment is challenging due to intrinsic antibiotic resistance. Bacteriophage therapy represents a potentially novel approach. Relatively few active lytic phages are av...
Kay, Alexander Mendez-Reyes, Jose Devezin, Tara Bakaya, Meenakshi Steffy, Teresa Dlamini, Sandile Msekandiana, Amos Ness, Tara Bacha, Jason Amuge, Pauline
...
Published in
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
There is insufficient evidence in children and adolescents with human immunodeficiency virus (CAHIV) to guide the timing of antiretroviral treatment (ART) initiation after starting treatment for pulmonary tuberculosis (pTB). To address this knowledge gap, we evaluated the risk of mortality associated with timing of ART initiation in ART-naive CAHIV...
Ross, Jonathan Brazier, Ellen Fatti, Geoffrey Jaquet, Antoine Tanon, Aristophane Haas, Andreas D Diero, Lameck Castelnuovo, Barbara Yiannoutsos, Constantin T Nash, Denis
...
Published in
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Treat-All guidelines recommend initiation of antiretroviral therapy (ART) for all people with HIV (PWH) on the day of diagnosis when possible, yet uncertainty exists about the impact of same-day ART initiation on subsequent care engagement. We examined the association of same-day ART initiation with loss to follow-up and viral suppression among pat...
Donlan, Alexandra N Mallawaarachchi, Indika Sasson, Jennifer M Preissner, Robert Loomba, Johanna J Petri, William A
Published in
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
We previously found that type 2 immunity promotes coronavirus disease 2019 (COVID-19) pathogenesis in a mouse model. To test relevance to human disease, we used electronic health record databases and determined that patients on dupilumab (anti-interleukin [IL]-4R monoclonal antibody that blocks IL-13 and IL-4 signaling) at the time of COVID-19 infe...
Bradley, Heather Hall, Eric W Asher, Alice Furukawa, Nathan W Jones, Christopher M Shealey, Jalissa Buchacz, Kate Handanagic, Senad Crepaz, Nicole Rosenberg, Eli S
...
Published in
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Public health data signal increases in the number of people who inject drugs (PWID) in the United States during the past decade. An updated PWID population size estimate is critical for informing interventions and policies aiming to reduce injection-associated infections and overdose, as well as to provide a baseline for assessments of pandemic-rel...
Alonso-Navarro, Rodrigo Cuesta, Genoveva Santos, Marta Cardozo, Celia Rico, Verónica Garcia-Pouton, Nicole Tuset, Montse Bodro, Marta Morata, Laura Puerta-Alcalde, Pedro
...
Published in
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
There is no reliable microbiological marker to guide the indication and the response to antiviral treatment in patients with coronavirus disease 2019 (COVID-19). We aimed to evaluate the dynamics of subgenomic RNA (sgRNA) in patients with COVID-19 before and after receiving treatment with remdesivir. We included consecutive patients admitted for CO...
